Kidney transplantation under FK 506.

PubWeight™: 7.45‹?› | Rank: Top 0.1%

🔗 View Article (PMC 2979318)

Published in JAMA on July 04, 1990

Authors

T E Starzl1, J Fung, M Jordan, R Shapiro, A Tzakis, J McCauley, J Johnston, Y Iwaki, A Jain, M Alessiani

Author Affiliations

1: Department of Surgery, University Health Center of Pittsburgh, PA 15213.

Articles citing this

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39

FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29

Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation (1993) 2.17

A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09

Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04

Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77

Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc (1993) 1.72

The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg (1996) 1.71

The question of FK 506 nephrotoxicity after liver transplantation. Transplant Proc (1991) 1.60

New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc (1991) 1.56

Adverse effects associated with the use of FK 506. Transplant Proc (1991) 1.41

Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. Transplant Proc (1991) 1.41

A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc (1991) 1.40

FK 506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc (1991) 1.37

Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr (2006) 1.36

Neurologic complications of FK 506. Transplant Proc (1991) 1.34

Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg (1994) 1.33

The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol (1993) 1.32

Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg (1992) 1.18

Tacrolimus in pediatric renal transplantation. Transplantation (1996) 1.18

Adverse effects of FK 506 overdosage after liver transplantation. Transplant Proc (1993) 1.18

The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc (1991) 1.16

A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy. Clin Transplant (1994) 1.15

A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation (1999) 1.14

A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. Transplant Proc (1995) 1.13

FK506 in pediatric kidney transplantation--primary and rescue experience. Pediatr Nephrol (1995) 1.11

Tacrolimus in renal transplantation. Transplant Proc (1996) 1.10

Expressive dysphasia possibly related to FK506 in two liver transplant recipients. Transplantation (1990) 1.04

Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation (1999) 1.00

Pediatric renal transplantation under FK 506 immunosuppression. Transplant Proc (1991) 0.98

Preliminary experience with FK506 in thoracic transplantation. Transplantation (1991) 0.97

Tacrolimus rescue therapy for renal allograft rejection--five-year experience. Transplantation (1997) 0.95

One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. Transplant Proc (1995) 0.94

The protective effect of FK506 pretreatment against renal ischemia/reperfusion injury in rats. Transplantation (1992) 0.91

History of clinical transplantation. World J Surg (2000) 0.91

Tryptophan dynamics of the FK506 binding protein: time-resolved fluorescence and simulations. Biophys J (1996) 0.90

Tacrolimus (FK506)-Associated Renal Pathology. Adv Anat Pathol (1997) 0.90

Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome. Transplant Proc (1991) 0.90

HLA and cross-reactive antigen group matching for cadaver kidney allocation. Transplantation (1997) 0.89

Transplantation of pediatric en bloc kidneys under FK 506 immunosuppression. Transplant Proc (1991) 0.89

Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen. Drug Des Devel Ther (2014) 0.85

The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience. Clin Transpl (1995) 0.85

Renal transplantation under FK 506 in African-Americans: early experience. Transplant Proc (1993) 0.83

Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study. Am J Transplant (2016) 0.82

Effects of cyclosporine and rapamycin on immunoglobulin production by preactivated human B cells. Clin Exp Immunol (1994) 0.81

Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. Transplant Proc (1991) 0.79

Pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients. Pediatr Nephrol (2009) 0.79

In vitro effects of cyclosporine and FK 506 on the renal cortex. Transplant Proc (1991) 0.78

Renal transplantation at the University of Pittsburgh: the impact of FK506. Clin Transpl (1994) 0.78

Outcome of tacrolimus conversion therapy for renal allograft rejection: 5-year follow-up. Transplant Proc (1999) 0.78

FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. Transplant Proc (1993) 0.77

The current status of hepatic transplantation at the University of Pittsburgh. Clin Transpl (1995) 0.76

Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience. Clin Transpl (1994) 0.76

Influence of conversion from calcineurin inhibitors to everolimus on fibrosis, inflammation, tubular damage and vascular function in renal transplant patients. Clin Exp Nephrol (2014) 0.76

Tacrolimus-based immunosuppression in pediatric renal transplantation. Transplant Proc (1999) 0.75

A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. J Urol (1998) 0.75

Failure of FK 506 to suppress the T cell-mediated immunity of mice to Listeria monocytogenes. Clin Exp Immunol (1993) 0.75

Notes on FK 506. Transplant Proc (1991) 0.75

Tacrolimus rescue therapy for renal transplant rejection. Transplant Proc (1996) 0.75

Early infections in kidney transplant recipients under FK 506. Transplant Proc (1991) 0.75

Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. Transplant Proc (1991) 0.75

Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. Am J Kidney Dis (1998) 0.75

Neuropsychiatric complications after liver transplantation: role of immunosuppression and hepatitis C. Dig Dis Sci (2006) 0.75

New immunosuppressive drugs: needs in and applications to pediatric transplantation. Eur J Pediatr (1992) 0.75

Articles cited by this

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc (1987) 8.45

FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) (1987) 7.07

A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature (1989) 7.02

Cyclosporine. N Engl J Med (1989) 5.67

A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature (1989) 5.53

Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) (1987) 4.54

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55

Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol (1987) 3.30

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66

Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39

Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37

The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31

The side effects of FK 506 in humans. Transplant Proc (1990) 2.08

FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94

Cyclosporine-induced hyperuricemia and gout. N Engl J Med (1989) 1.67

Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc (1990) 1.56

Steroid diabetes in renal transplant recipients: pathogenetic factors and prognosis. Surgery (1973) 1.43

Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA (1989) 1.40

In vitro effects of FK-506 on human and rat islets. Transplantation (1990) 1.35

The effect of FK 506 and CyA on the Lewis rat renal ischemia model. Transplant Proc (1990) 1.28

Successful sequential liver-kidney transplantation in a patient with performed lymphocytotoxic antibodies. Transplant Proc (1987) 1.25

Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Relationship to primary and regraft outcome. Transplantation (1989) 1.16

Juvenile-onset diabetes HLA-A, -B, -C, and -DR alloantigens. Diabetes (1979) 1.13

Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. Transplantation (1991) 1.13

HLA-D--related (DRw) antigens in juvenile diabetes mellitus. Diabetes (1979) 1.12

Effects of cyclosporin on insulin and C-peptide secretion in healthy beagles. Diabetes (1989) 1.01

Renal Transplantation in the Presence of a Positive Cytotoxic Antibody. Transplant Proc (1988) 0.99

Flow cytometry crossmatching in human cadaver kidney transplantation. Transplant Proc (1987) 0.98

Pancreatic islet transplantation in cynomolgus monkeys. Initial studies and evidence that cyclosporine impairs glucose tolerance in normal monkeys. Transplantation (1989) 0.97

Improved graft survival for flow cytometry and antihuman globulin crossmatch-negative retransplant recipients. Transplantation (1990) 0.93

Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. Transplant Proc (1990) 0.91

Articles by these authors

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. Am J Clin Pathol (1978) 6.88

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 6.54

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86

Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

Nucleic acid reactivity and conformation. II. Reaction of cytosine and uracil with sodium bisulfite. J Biol Chem (1973) 4.44

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01

X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet (2001) 3.86

The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med (2001) 3.85

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

Prevalence of Alzheimer's disease and other dementias in rural India: the Indo-US study. Neurology (1998) 3.82

Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther (1998) 3.77

Transplantation of multiple abdominal viscera. JAMA (1989) 3.59

Implementation of a high-sensitivity Micro-Angiographic Fluoroscope (HS-MAF) for in-vivo endovascular image guided interventions (EIGI) and region-of-interest computed tomography (ROI-CT). Proc SPIE Int Soc Opt Eng (2008) 3.49

TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity (2001) 3.43

The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant (2011) 3.42

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Accuracy of four commercial systems for identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. J Clin Microbiol (1996) 3.20

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

A multifactorial system for equitable selection of cadaver kidney recipients. JAMA (1987) 3.01

Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95

Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95

Deamination of cytosine derivatives by bisulfite. Mechanism of the reaction. J Am Chem Soc (1974) 2.92

Human thymic stromal lymphopoietin preferentially stimulates myeloid cells. J Immunol (2001) 2.85

Equitable allocation of extrarenal organs: with special reference to the liver. Transplant Proc (1988) 2.85

Allospecificity of activated T cells grown from endomyocardial biopsies from heart transplant patients. Transplantation (1986) 2.82

Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat Genet (1997) 2.81

Successful liver transplantation from crossmatch-positive donors. Transplant Proc (1981) 2.80

Interaction of the influenza virus nucleoprotein with the cellular CRM1-mediated nuclear export pathway. J Virol (2001) 2.76

Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75

The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med (1995) 2.68

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66

Medical education and health for all. Aust J Public Health (1995) 2.65

The prognostic value of kidney transplant center report cards. Am J Transplant (2013) 2.64

Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol (2013) 2.51

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49

Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48

Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48

Maternal feeding practices and beliefs and their relationships to overweight in early childhood. J Dev Behav Pediatr (2001) 2.39

Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39

Liver transplantation across ABO blood groups. Surgery (1986) 2.39

Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J Virol (1999) 2.37

Thoracic duct drainage before and after cadaveric kidney transplantation. Surg Gynecol Obstet (1979) 2.33

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32

Characterization of influenza virus RNA complete transcripts. Virology (1982) 2.31

Liver transplantation for type IV glycogen storage disease. N Engl J Med (1991) 2.31

The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31

The deamination of cytidine and cytosine by acidic buffer solutions. Mutagenic implications. Biochemistry (1966) 2.30

FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29

Homeostasis of alpha beta TCR+ T cells. Nat Immunol (2000) 2.29

Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J (1999) 2.28

The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect Control Hosp Epidemiol (1999) 2.28

Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26

Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25

On the reaction of guanine with glyoxal, pyruvaldehyde, and kethoxal, and the structure of the acylguanines. A new synthesis of N2-alkylguanines. Biochemistry (1969) 2.25

Overview: deinstitutionalization of psychiatric patients, a critical review of outcome studies. Am J Psychiatry (1981) 2.24

Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24

Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res (2001) 2.22